Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls

Summary

Individuals with elevated levels of plasminogen activator inhibitor type 1 are at risk of developing atherosclerosis. The mechanisms leading to increased plasma PAI-1 concentrations are not well understood. The link observed between increased PAI-1 levels and insulin resistance has lead workers to investigate the effects of insulin or triglyceride rich lipoproteins on PAI-1 production by cultured hepatocytes or endothelial cells. However, little is known about the contribution of these cells to PAI-1 production in vivo. We have studied the expression of PAI-1 in human liver sections as well as in vessel walls from different territories, by immunocytochemistry and in situ hybridization.

We have observed that normal liver endothelial cells expressed PAI-1 while parenchymal cells did not. However, this fact does not refute the role of parenchymal liver cells in pathological states.

In healthy vessels, PAI-1 mRNA and protein were detected primarily at the endothelium from the lumen as well as from the vasa vasorum. In normal arteries, smooth muscle cells were able to produce PAI-1 depending on the territory tested. In deeply altered vessels, PAI-1 expression was observed in neovessels scattering the lesions, in some intimal cells and in smooth muscle cells. Local increase PAI-1 mRNA described in atherosclerotic lesions could be due to the abundant neovascularization present in the lesion as well as a raised expression in smooth muscle cells. The increased PAI-1 in atherosclerosis could lead to fibrin deposit during plaque rupture contributing further to the development and progression of the lesion.

• References

• 1 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 2 Hamsten A, Walldius G, Szamosi A, Blombäck M, De Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9
• 3 Barbash GI, Hod H, Roth A, Miller HI, Rath S, Harzahav Y, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-1235
• 4 Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor 1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992; 68: 60-63
• 5 Levi M, Biemond BJ, Van Zonneveld AJ, Ten Cate JW. Pannekoek H. Inhibition of plasminogen activator inhibitor 1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312
• 6 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor 1 gene. Nature 1990; 346: 74-76
• 7 Vague P, Juhan-Vague I, Ailhaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 2: 250-253
• 8 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and athero-thrombosis. Diabetologia 1991; 34: 457-462
• 9 Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemost 1987; 57: 326-328
• 10 Grant PJ, Stickland MH, Booth NA, Prentice CRM. Metformin causes a reduction in basal and postvenous occlusion plasminogen activator inhibitor 1 in type 2 diabetic patients. Diab Med 1991; 8: 361-365
• 11 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-494
• 12 Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type 1 in endothelial cells. Diabetes 1992; 41: 890-895
• 13 Grant PJ, Ruegg M, Medcalf RL. Basal expression and insulin mediated induction of PAI-1 mRNA in HepG2 cells. Fibrinolysis 1991; 5: 81-86
• 14 Kooistra T, Bosma PJ, Tons HAM, Van Den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723-728
• 15 Schneiderman J, Sawdey M, Craig H, Thinnes T, Bordin G, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy. Am J Pathol 1993; 143: 753-762
• 16 Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993; 70: 135-137
• 17 Loskutoff DJ, Keeton M, Ahn C, Sawdey M, Schneiderman J, Olman M, Feams C, Almus F. Analysis of the vascular wall by in situ hybridization. Fibrinolysis 1992; 6: 20 (Abstract).
• 18 Fujii S, Sawa H, Saffitz JE, Lucore CL, Sobel BE. Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo. Circulation 1992; 86: 2000-2010
• 19 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143
• 20 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002
• 21 Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dano K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-1680
• 22 Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Wille-brand factor. Proc Natl Acad Sci USA 1985; 82: 6394-6398
• 23 Chung DW, Que BG, Rixon MW, Mace M, Davie EW. Characterization of complementary deoxyribonucleic acid and genomic deoxyribonucleid acid for the p chain of human fibrinogen. Biochemistry 1983; 22: 3244-3250
• 24 Melton DA, Krieg PA, Rebagliati MR, Maniatis T, Zinn K, Green MR. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucl Acid Res 1984; 12: 7035-7056
• 25 Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerosis plaques by in situ hybridization. J Clin Invest 1988; 82: 1134-1143
• 26 Höltke HJ, Kessler C. Non-radioactive labeling of RNA transcripts in vitro with the hapten digoxigenin (DIG); hybridization and ELISA based detection. Nucl Acid Res 1990; 18: 5843-5851
• 27 Declerck PJ, Alessi MC, Vertreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody, based on enzyme-linked immunoadsorbant assay. Blood 1988; 71: 220-225
• 28 Miller LL, Bale WF. Synthesis of all plasma proteins except gamma globulins by the liver. J Exp Med 1954; 99: 125
• 29 Raum D, Marcus D, Alper CA, Levey R, Taylor PD, Starzl TE. Synthesis of human plasminogen by the liver. Science 1980; 208: 1036
• 30 Bakker CM, Metselaar HJ, Groenland TN, Gomes MJ, Knot EAR, Hesse-link EJ, Schalm SW, Stibbe J, Terpstra OT. Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: The role of the anhepatic period. Hepatology 1992; 16: 404-408
• 31 Van Den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, Van Hinsberg VWM. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemost 1988; 60: 63-67
• 32 Quax PHA, Van Den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, Van Berkel TJC, Kuiper J, Emeis JJ. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265: 15560-15563
• 33 Kuiper J, Kamps JAAM, Van Berkel TJC. Identification of the inhibitor of the plasminogen activator as the major protein secreted by endothelial rat liver cells. FEBS Lett 1989; 245: 229-234
• 34 Varagona G, Brown D, Haase A, Dusheiko G. Increased steady-state levels of alpha-fetoprotein mRNA in hepatocellular carcinoma: an analysis by in situ hybridization. Liver 1992; 12: 62-68
• 35 Wilcox JN. Analysis of local gene expression in human atherosclerotic plaques by in situ hybridization. Trends Cardiovasc Med 1991; 1: 17-24
• 36 Gordon D, Augustine AJ, Smith KM, Schwartz SM, Wilcox JN. Localization of cells expressing t-PA, PAI-1 and urokinase by in situ hybridization in human atherosclerotic plaques and in the normal rhesus monkey. Thromb Haemost 1989; 419: 131
• 37 Sawa H, Fuji S, Sobel BE. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arteriosclerosis and Thrombosis 1992; 12: 1507-1515
• 38 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-1100
• 39 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843